MedTrace Logo

Determining Optimal Post-Stroke Exercise (DOSE)

NCT01915368 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-12-16

No results posted yet for this study

Summary

The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.

Conditions

  • Cerebrovascular Accident
  • Stroke
  • Cerebral Infarction
  • Brain Infarction
  • Brain Ischemia
  • Cerebrovascular Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Vascular Diseases

Interventions

BEHAVIORAL

Stroke Management Program (SMP)

Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors

BEHAVIORAL

Stroke Monitoring Program (SMonP)

Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors

BEHAVIORAL

Stroke Supplementary Program (SSP)

Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Janice Eng, PhD · The University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915368 on ClinicalTrials.gov